TX-SOFTSERVE
11.2.2021 13:02:13 CET | Business Wire | Press release
SoftServe , a leading digital authority and consulting company, today announced that it has successfully achieved the VMware Cloud on AWS VMware Master Services Competency. This competency demonstrates that SoftServe is committed to helping organizations accelerate their digital transformations by leveraging their validated services delivery capabilities around advanced VMware technologies.
“As a VMware Principal Partner, SoftServe has advanced technical proficiency, delivery expertise, and proven customer success in deploying hybrid cloud solutions using VMware Cloud on AWS,” said Todd Lenox, Vice President, Global Alliances and Partnerships at SoftServe. “Our ability to provide customers with a smooth and seamless transition to the Cloud allows them to run applications across a VMware Cloud Infrastructure environment with access to a broad range of AWS services.”
“VMware is pleased to recognize SoftServe for achieving the VMware Cloud on AWS Master Services Competency. This achievement shows customers that partners like SoftServe are invested, dedicated, and have validated expertise in advanced VMware technologies,” said Sandy Hogan, SVP of Worldwide Commercial and Partner Sales, VMware. “We value SoftServe as a VMware partner, and appreciate their efforts in achieving this VMware distinction.”
VMware Master Services Competencies are designed to help partners demonstrate customer-centric solutions and technical proficiency, with proven success and expertise in a specialized area of business. These competencies also allow partners to differentiate in five specific solution areas.
VMware partners can achieve VMware Master Services Competencies in:
- Cloud Management and Automation – Designates expertise in delivery of VMware Cloud Management and Automation solutions and services with deep understanding and execution of cloud management design principles and methodologies.
- Data Center Virtualization – Designates expertise in delivery of VMware vSphere environments and digital infrastructure services with deep understanding of and execution in Data Center Virtualization design principles and methodologies.
- Desktop and Mobility – Designates expertise in designing, installing, and maintaining VMware Workspace ONE and VMware Horizon solutions with deep understanding of and execution in desktop and mobility design principles and methodologies to deliver a scalable and reliable digital workspace.
- Network Virtualization – Designates expertise in the delivery of VMware NSX environments and services with deployment and optimization of NSX environment capabilities.
- VMware Cloud on AWS – Designates expertise in the delivery of hybrid cloud solutions based on VMware Cloud on AWS. This service provides an operationally consistent and familiar way to run, manage and secure applications in a hybrid IT environment.
The VMware Partner Connect program empowers partners with the flexibility to meet customers’ needs, making VMware technologies and services more accessible. Partners have an enhanced experience that delivers simplicity, choice and innovation, and recognizes and rewards partners based on the value they bring to customers.
SoftServe implements VMware-powered solutions by leveraging its expertise in cloud adoption, DevOps, and end-to-end app modernization services. With advanced software development and automation success, SoftServe facilitates reduced development cycle times and deployment costs while delivering speed, agility, and greater efficiency at scale.
For more information, please visit SoftServe’s VMware partner page .
About SoftServe
SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, energy, financial services, software, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients’ users expect.
SoftServe delivers open innovation—from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience is built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy. No matter where you are in your journey.
Visit our website , blog , LinkedIn , Facebook , and Twitter pages.
VMware, vSphere, Workspace ONE, Horizon, and NSX are registered trademarks or trademarks of VMware, Inc. in the United States and other jurisdictions. All other marks and names mentioned herein may be trademarks of their respective companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005012/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom